

AMENDMENT TRANSMITTAL LETTER (Small Entity)Applicant(s): **SZALAY, Aladar A. et al.**

Docket No.

11785-3

Application No. 09/786,377	Filing Date March 1, 2001	Examiner DO, Pensee T.	Customer No. 23676	Group Art Unit 1641	Confirmation No. 8166
--------------------------------------	-------------------------------------	----------------------------------	------------------------------	-------------------------------	---------------------------------

Invention: **METHOD FOR STUDYING PROTEIN INTERACTIONS IN VIVO**COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

Applicant claims small entity status. See 37 CFR 1.27

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	32	32 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	4	4 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable)		<input type="checkbox"/>			\$0.00
				TOTAL ADDITIONAL FEE FOR THIS AMENDMENT	\$0.00

No additional fee is required for amendment.

Please charge Deposit Account No. _____ in the amount of _____

A check in the amount of _____ to cover the filing fee is enclosed.

The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-2090

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 CFR 1.17.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Signature

David A. Farah, M.D. Reg. No. 38,134
SHELDON & MAK PC
225 South Lake Avenue, Suite 900
Pasadena, California 91101
Tel: (626) 796-4000
Fax: (626) 795-6321
eMail: davidf@usip.com


Dated: **August 29, 2005**


I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on **August 29, 2005**

(Date)

*Signature of Person Mailing Correspondence**Typed or Printed Name of Person Mailing Correspondence*cc: **Loma Linda University**



CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No. 11785-3
Application Serial No. 09/786,377	Filing Date March 1, 2001	Examiner DO, Pensee T.	Group Art Unit 1641
Inventor(s): SZALAY, Aladar A. et al.			
Invention: METHOD FOR STUDYING PROTEIN INTERACTIONS <i>IN VIVO</i>			
<p>I hereby certify that the following correspondence:</p> <ol style="list-style-type: none">1. Amendment Transmittal Letter (Small Entity) (1 page)2. Response and Amendment (14 pages)3. Acknowledgment of Receipt Postcard <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: August 29, 2005</p> <p>(Date)</p> <p>_____ Marilyn Paik (Typed or Printed Name of Person Mailing Paper or Fee)</p> <p>_____  (Signature of Person Mailing Correspondence)</p> <p>EV629341166US ("Express Mail" Mailing Label No. EV 629341166 US)</p>			



09/786,377

11785-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

) Group Art Unit: 1641
)
 SZALAY, Aladar A. et al.) Examiner: DO, Pensee T.
)
 Serial No.: 09/786,377) Confirmation No. 8166
)
 Filed: March 1, 2001)
)
 For: Method for Studying Protein)
 Interactions *in Vivo*) Pasadena, California
)

RESPONSE AND AMENDMENT

Mail Stop Amendment
 COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This is a response to the Office Action dated June 28, 2005. Please amend the above-identified United States patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 8 of this paper.